Cite
HARVARD Citation
Orkin, C. et al. (2019). Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies. Journal of infection and public health. 12 (1), pp. 147-. [Online].